drugset / Trial / NCT01271998

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT01271998

Phase 1 Completed 20 enrolled Merck & Co., Inc.
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The primary purpose of this study is to determine the steady-state plasma pharmacokinetics (PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy volunteers.

Timeline

Start
2010-12-08
Primary completion
2011-01-03
Completion
2011-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tedizolid Small molecule 200 mg Oral